Laurie J. Gordon

Pediatrics

525 E 68th St
New York, NY 10065

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Orthogonal IMiD-Degron Pairs Induce Selective Protein Degradation in Cells.

Orthogonal IMiD-Degron Pairs Induce Selective Protein Degradation in Cells.

Journal: ACS chemical biology

Published: November 02, 2025

Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787.

Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787.

Journal: Journal of medicinal chemistry

Published: June 12, 2024

Orthogonal IMiD-Degron Pairs Induce Selective Protein Degradation in Cells.

Orthogonal IMiD-Degron Pairs Induce Selective Protein Degradation in Cells.

Journal: bioRxiv : the preprint server for biology

Published: April 01, 2024

Development of an intracellular quantitative assay to measure compound binding kinetics.

Development of an intracellular quantitative assay to measure compound binding kinetics.

Journal: Cell chemical biology

Published: December 22, 2023

Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432.

Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432.

Journal: Journal of medicinal chemistry

Published: November 15, 2022

Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate.

Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate.

Journal: Journal of medicinal chemistry

Published: January 07, 2022

Optimization of a Series of RIPK2 PROTACs.

Optimization of a Series of RIPK2 PROTACs.

Journal: Journal of medicinal chemistry

Published: August 25, 2021

Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.

Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.

Journal: Journal of medicinal chemistry

Published: August 13, 2021

Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors.

Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors.

Journal: Journal of medicinal chemistry

Published: July 14, 2021

Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors.

Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors.

Journal: Journal of medicinal chemistry

Published: July 13, 2021

Optimization of Naphthyridones into Selective TATA-Binding Protein Associated Factor 1 (TAF1) Bromodomain Inhibitors.

Optimization of Naphthyridones into Selective TATA-Binding Protein Associated Factor 1 (TAF1) Bromodomain Inhibitors.

Journal: ACS medicinal chemistry letters

Published: May 21, 2021

Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors.

Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors.

Journal: Journal of medicinal chemistry

Published: March 04, 2021

Showing 1-12 of 35

Last Updated: 09/26/2026